Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 14;9:660005. doi: 10.3389/fcell.2021.660005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wei, Wang, Wang, Liu, Wan, Yuan, Li, Ma and Liu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Sorafenib enhanced TMZ cytotoxicity in glioma cell lines. (A,B) Glioma cell lines, including U251 and SHG-44, were treated with varying concentrations of temozolomide (abbreviated as TMZ) for 24 or 48 h. MTT assay showed that TMZ significantly decreased the viabilities of glioma cells in a time- and dose-dependent manner. (C,D) U251 and SHG-44 cells were treated with 2 μM sorafenib and 100 μM TMZ for 24 h. (C) Flow cytometry with Annexin V and PI double staining showed that the combination of sorafenib and TMZ strikingly induced the apoptosis of glioma cells. (D) Cells stained with Hoechst 33342 demonstrated that the combination of sorafenib and TMZ induced apoptotic changes to chromatin in U251 cells after 24 h (20×) (Scale bar = 10 μm).